DPP4 is the enzyme that breaks down GLP-1, so by inhibiting DPP4, GLP-1 may hang around in the system longer
This central action supports our patients in managing their eating behaviors more effectively, which is essential for sustainable weight loss
Side effect management Injection guidance Medication access support Lifestyle tips while titrating or tapering medication Nutrition New food innovations to support GLP-1 members with nutritional adjustments
Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease
"With these positive data in hand, we are now planning to submit orforglipron for regulatory review by year-end and are prepared for a global launch to address this urgent public health need." According to Eli Lilly, adults in the Phase 3 trials all lost weight with orforglipron and on the highest dose of 36 mg of orforglipron, the trial participants lost about 27 pounds over the course of 72 weeks or about 12% of their body weight, which is meaningful but not quite as high as some injectables
In terms of market initiatives, collaborations like that of Novo Nordisk and Eli Lilly on integrated GLP-1 therapies demonstrate successful partnerships driving innovation